Published in Women's Health Weekly, January 8th, 2004
The results appeared in the December 17, 2003, issue of the Journal of the National Cancer Institute.
ER-negative breast cancers are not dependent on estrogen to grow and do not respond to anti-estrogen drugs such as tamoxifen and raloxifene. ZD1839, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, blocks the cellular signaling pathway that contributes to tumor survival and growth, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.